Navigation Links
InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
Date:6/29/2010

sensitization is a core therapeutic mechanism for addressing the Type 2 Diabetes epidemic," added Dr. Linda Higgins, President & Chief Operating Officer of InteKrin Therapeutics. "INT131 besylate offers a potential significant advance in addressing the critical need for a safe insulin sensitizer."

About INT131:

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of Type 2 Diabetes. As a selective PPAR-gamma modulator (SPPARM), INT131 has been designed to provide potent glucose lowering and durability of effect without the recognized side effects of the currently available insulin sensitizers which, unlike INT131, are full PPAR-gamma agonists. InteKrin has completed an End-Of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for INT131 and is moving the program into Phase 3 development.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clini
'/>"/>

SOURCE InteKrin Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
3. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
4. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
5. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
6. InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...  Seres Health, a clinical-stage therapeutics company developing ... microbiome, announced today that Dr. David Cook ... Chief Scientific Officer, will be presenting at the ... (ICAAC). The presentation will highlight the scientific and ... bacterial spores derived from the human microbiome, and ...
(Date:8/28/2014)... PITTSBURGH , Aug. 28, 2014 /PRNewswire-iReach/ -- ... exhibiting at the 9 th Annual Global ... , September 8-9 th . The Global ... industry leaders in small molecule and biologic pharmaceutical ... address challenges that today,s manufacturers face, such as ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com ... report is available in its catalogue: ... Asia-Pacific Markets to 2020 - Novel ... in Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... WILMINGTON, Del., Oct. 26 Next Intelligence Corporation ( ... today announced the expansion of its channel program for ... and system integrators (SI) to explore the growing health ... members sales leads, education on technical and selling aspects ...
... (Nasdaq: GTIV ), the nation,s largest provider of ... present at the Oppenheimer 21st Annual Healthcare Conference in New ... and the Credit Suisse 2010 Healthcare Conference in Phoenix, AZ ... 10, 2010. The presentations will be available to ...
Cached Medicine Technology:Next Intelligence Health Expands US Channel Program 2Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 2Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 3
(Date:8/29/2014)... August 29, 2014 Glendale Botox ... promotion on Botox throughout the month of September. This special ... of two syringes of Juvederm. Patients can take advantage of ... skin. The Glendale Botox experts will work with patients to ... , What is Botox? , Botox is a ...
(Date:8/29/2014)... The way that parents respond to their infant,s babbling ... suggests. Over six months, researchers observed the interactions ... The sessions were 30 minutes long and happened twice ... the start of the study. When parents listened ... form complex sounds. The babies whose parents responded to ...
(Date:8/29/2014)... 29, 2014 Empty Nest Syndrome ... http://www.blogtalkradio.com/dr-carol-francis/2014/08/29/psychologist-dr-carol-francis-addressing-empty-nest-syndrome .     , Mothers and fathers, who ... marital bliss, prodding, laughing and sweating through parenting, ... this week. Relief and parenting pride intermix ... Dr. Carol Francis as a Clinical ...
(Date:8/29/2014)... TayganPoint Consulting Group, a leading strategic ... time, Inc. Magazine has named the company one of ... on solid revenue growth of over 166% over the ... the list. TayganPoint’s repeat success in this ranking, ... few years, is a demonstration of its strong business ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Fat is ... and bad fat. Brown fat is usually stored in the ... white fat typically reveals itself in overflowing bellies, muffin tops, ... fats occur naturally in many foods and promote better health, ... risks, including elevated bad cholesterol levels and lower good cholesterol ...
Breaking Medicine News(10 mins):Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Encouraging Your Baby's Babbling May Speed Language Development 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 3Health News:Diet Doc Announces Modernized, Interesting and Easy to Follow Diet Plans that Deliver Fast Weight Loss and Teach Patients the Difference Between Good and Bad Fat 2Health News:Diet Doc Announces Modernized, Interesting and Easy to Follow Diet Plans that Deliver Fast Weight Loss and Teach Patients the Difference Between Good and Bad Fat 3
... , FRIDAY, Feb. 18 (HealthDay News) -- Patients with ... radiation treatments have a much lower long-term survival rate than ... the study of patients with squamous cell carcinoma of the ... to smoke were still alive five years after treatment, compared ...
... Scientists at the Children,s Center for Cancer and Blood ... Los Angeles today announced a breakthrough discovery in understanding ... a protein called CD19-ligand (CD19-L) located on the surface ... and destruction of leukemia cells by the immune system. ...
... 18 (HealthDay News) -- Speaking more than one language may ... that bilingual speakers outperform people who speak only one language ... irrelevant information to focus on important information. This means bilingual ... than one project at a time, said Judith Kroll, ...
... bigger role in the American health care system, argued ... conference of the American Association for the Advancement of ... health care costs depend on the policy context in ... Meltzer, Associate Professor of Medicine, in his presentation, "Policies ...
... leading lung cancer screening researchers, doctors and advocates. ... Early Lung Cancer Action Program (I-ELCAP) Screening Conferences. ... International Early Lung Cancer Action Program (I-ELCAP) and ... International Lung Cancer Consortium (ILCCO). This meeting ...
... (Feb 18, 2011) James C. Wittig, M.D., chief ... the John Theurer Cancer Center at Hackensack University Medical ... approaches to orthopedic oncology at the upcoming American Academy ... inventing some of the most-used best practices in limb-sparing ...
Cached Medicine News:Health News:Smoking During Head & Neck Cancer Therapy Tied to Poor Outcome 2Health News:Scientists bioengineer a protein to fight leukemia 2Health News:Cost-effectiveness research needs to be considered in developing new medical technology 2Health News:World's largest lung cancer screening conference to address benefits of CT scans 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 3Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 4Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 5Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 6Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 7
The ZEPHIR Anterior Cervical Plate System is the lowest profile plate clinically available....
... The Philips Mx8000 IDT six-slice imaging ... incorporating leading technological innovations to maximize ... influencing departmental efficiency to delivering optimal ... the platform for multislice CT today ...
... Sharing the same proprietary Quantum detector technology ... a combination of speed and resolution not available ... to fit your clinical and budgetary needs, the ... a dedicated upgrade path to 16 slice productivity., ...
... TLIF Instruments are designed to facilitate disc ... bone graft during interbody fusion. The TLIF ... easy use during TLIF, for which they ... be used very effectively in PLIF and ...
Medicine Products: